BROADCASTS.com

World-renowned lipidologist Tom Dayspring returns to give an update on the current thinking in lipidology as a follow-up to his 2018 five-part podcast series. In this episode, Tom discusses the growing consensus that atherogenic lipoproteins are essential drivers of atherosclerotic vascular disease. Tom further emphasizes apolipoprotein B (apoB) and lipoprotein(a) (Lp(a)). He provides insights into risk assessment, including which lab metrics to use, how to interpret them, and the appropriate therapeutic targets. Additionally, Tom discusses the most recent developments in lipid-lowering drug therapies\u2014from the continued evolution of PCSK9 inhibitors, to the latest understanding of EPA and DHA, and the most recent addition of bempedoic acid to the list of therapeutic agents.

We discuss:

• The latest in the field of lipidology and cardiovascular disease [3:45];
• Apolipoproteins\u2014the key to understanding lipid biology [9:30];
• ApoB as a preferred metric over LDL-P [16:30];
• Therapeutic goals for apoB concentration [21:45];
• Drivers of atherosclerosis [34:15];
• Overview and current thinking on high density lipoproteins (HDLs)\u2014Is it a useful metric? [37:00];
• Lipoprotein(a)\u2014the most dangerous particle you\u2019ve never heard of [55:00];
• Are low density lipoprotein triglycerides (LDL-TGs) a useful metric? [1:13:15];
• Tom\u2019s preferred lab measurements [1:17:45];
• The latest in lipid-lowering therapies [1:21:30];
• The different pathways among various lipid-lowering drugs [1:30:45];
• The latest on EPA and DHA [1:38:15];
• Fibrates\u2014an underappreciated treatment for hypercholesterolemia [1:49:45] and;
• More.

Learn more:\xa0https://peterattiamd.com/

Show notes page for this episode: https://peterattiamd.com/tomdayspring6\xa0

Subscribe to receive exclusive subscriber-only content:\xa0https://peterattiamd.com/subscribe/

Sign up to receive Peter's email newsletter:\xa0https://peterattiamd.com/newsletter/

Connect with Peter on Facebook | Twitter | Instagram.